CompletedNot Applicable

Efficacy and Safety of Oral Rivaroxaban in Cerebrosinovenous Thrombosis

Pakistan75 participantsStarted 2023-12-01

Plain-language summary

The study seeks to fill the gaps regarding safety and efficacy of rivaroxaban and standard anticoagulant. therefore the current study was planned with the aim to determine the safety and efficacy of rivaroxaban and standard anticoagulant in the treatment of cerebrosinovenous thrombosis (CSVT).

Who can participate

Age range2 Months – 18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Any gender * Aged 2 months to 18 years * Patients presenting with CSVT evident by computed tomography (CT) or magnetic resonance venography (MRV). Exclusion Criteria: * Patients having active bleeding or having high risk of bleeding * Estimated glomerular filtration rate \< 30 milliliter/minute per 1.73 m2.

What they're measuring

Treatment efficacy

Timeframe: 3 months

Trial details

NCT IDNCT07523347

SponsorMuhammad Aamir Latif

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-12-31

View on ClinicalTrials.gov More Cerebrosinovenous Thrombosis trials